Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
Study shows 6 years of adjuvant imatinib significantly reduces relapse risk in high-risk GIST patients.
New trial evaluates ripretinib vs sunitinib in advanced GIST patients with specific KIT mutations
Phase 2 trial finds ripretinib effective and safer than sunitinib for advanced GIST in Chinese patients.